Navigation Links
Ardea to Present Data on Lead HIV Candidate, RDEA806, at XVII International AIDS Conference
Date:7/17/2008

preclinical development and is believed to be an inhibitor of the URAT1 transporter in the kidney, which is responsible for regulation of uric acid levels. We are evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients, as well as in a Phase 1 study in normal healthy volunteers as a precursor to trials in patients with inflammatory diseases. Lastly, we have evaluated our second-generation MEK inhibitor for the treatment of cancer and inflammatory diseases, RDEA436, in a human micro-dose pharmacokinetic study and have selected it as a development candidate.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our goals, including the expected properties and benefits of RDEA806, RDEA427, RDEA594, RDEA119, RDEA436 and our other compounds and the results of preclinical, clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, and costs associated with our drug discovery and development programs and business development activities. These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect even
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Ardea Biosciences Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout
2. Craig Johnson Joins Ardea Biosciences Board of Directors
3. Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology
4. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008
5. Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses
6. Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences
7. Ardea to Present at Cowen and Companys 28th Annual Health Care Conference
8. Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego
9. Ardea Biosciences Establishes Scientific Advisory Board for Inflammation Program
10. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
11. Ardea Biosciences Establishes Scientific Advisory Board for HIV Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Boston Scientific Corporation (NYSE: BSX ) today ... billion aggregate principal amount of its senior notes under ... consists of $850 million of 4.50 percent notes due ... January 2020 and $300 million of 7.375 percent notes ... the net proceeds for general corporate purposes, including prepaying ...
(Date:12/14/2009)... Nektar Therapeutics (Nasdaq: NKTR ) ... to serve on its board of directors. ... over 35 years of experience in corporate management, ... Nektar extensive industry perspective at an important time ... President and CEO of Nektar and member of ...
(Date:12/14/2009)... company, has completed the delivery of Brookfield Engineering’s Powder Flow ... plastic enclosure with a smaller footprint and more compact design. ... ... 14, 2009 -- ThermoFab, a US-based thermoforming company, has completed ... Brookfield move from sheet metal to a plastic enclosure with ...
(Date:12/11/2009)... -- EntreMed, Inc. (Nasdaq: ENMD ), today ... revenue from sales of Thalomid® during the third ... million. In addition, the Company anticipates a ... fiscal 2009. The difference in estimated and ... reflected in the fourth quarter financial results. ,, ...
Breaking Biology Technology:Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3Dennis Winger Joins Nektar Therapeutics' Board of Directors 2Dennis Winger Joins Nektar Therapeutics' Board of Directors 3Thermofab Helps Brookfield Engineering Move To A Compact Custom Plastic Enclosure 2EntreMed Reports Receipt of Third Quarter Royalty Payment 2
... Rankings Include 170 Hospitals and Medical Centers in 16 Specialties, ... 19 Hospitals Included in ... Group today,announced the 2008 publication of America,s Best Hospitals, accessible,today ... July 14., Authoritative and influential, the 2008 America,s Best ...
... SHANGHAI, China, July 11 /Xinhua-PRNewswire/ -- WuXi ... medical device research,and development outsourcing company with ... proudly announced that it has won the ... Class Outsourced R&D in Pharmaceuticals and,Biotechnology., ...
... Molecular Biology Laboratory (EMBL) discovered a new way to make ... method that compares how similar the side effects of different ... the same target molecule. The study, published in Science ... , Similar drugs often share target proteins, modes of action ...
Other Biology Technology:U.S. News Media Group Releases 19th Edition of America's Best Hospitals 2U.S. News Media Group Releases 19th Edition of America's Best Hospitals 3WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology 2WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology 3Teaching old drugs new tricks 2
(Date:12/13/2009)... Yale University researchers has used nanosensors to measure ... time. Their findings, which appear December 13 in ... , could dramatically simplify the way physicians test ... , The teamled by Mark Reed, Yale,s ... and Tarek Fahmy, an associate professor of biomedical ...
(Date:12/11/2009)... "green" trend, educators worldwide are relying more ... science knowledge. Studies have revealed that bringing ... just science scoresenvironmental-based lessons can also improve ... Naturally, educators are interested in developing new ... the classroom in hopes of piquing student ...
(Date:12/11/2009)... plants photosynthesize, absorb carbon dioxide and produce oxygen, ... photosynthesis has had on Earth. One of those ... of photosynthesis is Jeffrey Touchman, assistant professor in ... Oxygen, one of the by-products of photosynthesis by ... algae and higher plants), transformed the Precambrian Earth ...
Breaking Biology News(10 mins):Scientists use nanosensors for first time to measure cancer biomarkers in blood 2Students learn environmental stewardship, improve science scores 2'Extreme' genes shed light on origins of photosynthesis 2'Extreme' genes shed light on origins of photosynthesis 3Communities Nationwide Learn Less Is More from Metabolife 28R 29 Through 1 000 In Home Parties and An Interactive Site www joinlessismore com 59003 1Communities Nationwide Learn Less Is More from Metabolife 28R 29 Through 1 000 In Home Parties and An Interactive Site www joinlessismore com 59003 2Communities Nationwide Learn Less Is More from Metabolife 28R 29 Through 1 000 In Home Parties and An Interactive Site www joinlessismore com 59003 3Henry Ford West Bloomfield Hospital Launches Gene Therapy Study for Parkinsons Disease 59000 1Henry Ford West Bloomfield Hospital Launches Gene Therapy Study for Parkinsons Disease 59000 2Botsford Hospital Cancer Center Earns Silver LEED Certification from the U S Green Building Council 58997 1Botsford Hospital Cancer Center Earns Silver LEED Certification from the U S Green Building Council 58997 2Botsford Hospital Cancer Center Earns Silver LEED Certification from the U S Green Building Council 58997 3
... Today,s opening of a new breast health center ... provide significant research opportunities for the Translational Genomics Research ... Center will include a tumor biorepository for TGen that ... ways to diagnose and treat breast cancer, which affects ...
... come in a variety of sizes and shapes, making ... Tomato Analyzer is "rapidly becoming the standard for fruit ... Talbot Brewer of The Ohio State University,s Department of ... Tomato Analyzer research were published in a recent issue ...
... industry has been growing rapidly since the mid-1980s, ... annually. Examples of nontimber forest products (NTFP) include ... herbal products, and specialty floral and decorative products. ... used to satisfy increasing consumer demand for herbal ...
Other Biology News:Breast health center gives TGen new research opportunities 2New and improved tomato analyzer 2Decreasing deer damage 2Decreasing deer damage 3
Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
WTAP Antibody...
Anti-Dardarin Immunogen: Synthetic peptide from rat LRRK2. Available Date: 38814...
... polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide derived ... C-terminus of Human MSY2/YBOX2. (Note: ... (Peptide available as ...
Biology Products: